GlaxoSmithKline has announced its platelet-boosting drug Revolade has gained EU approval for treating patients with the hepatitis C virus. Read our article on the news here:
GlaxoSmithKline has announced its platelet-boosting drug Revolade has gained EU approval for treating patients with the hepatitis C virus. Read our article on the news here: